Drug intelligence / Profile preview

[68Ga]Ga-Sa-DABI-4

Development stage: Phase 1
Lead developer: Chongqing Medical University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-Sa-DABI-4 is a radiopharmaceutical diagnostic agent used with positron emission tomography (PET) for imaging stimulator of interferon gene (STING) expression in cancer patients. STING protein plays a vital role in the immune surveillance of tumor microenvironment. This agent combines the radionuclide gallium-68 with a targeting molecule (Sa-DABI-4) designed to bind to STING proteins.

Other names: 68Ga-Sa-DABI-4

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on [68Ga]Ga-Sa-DABI-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-Sa-DABI-4.

Explore the full profile